Anticoagulant Options — Why the FDA Approved a Higher but Not a Lower Dose of Dabigatran

Last fall, the FDA approved dabigatran, in a 150-mg dose only, for reducing risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. A 110-mg regimen was also effective, but the agency believes that patients should receive the higher dose.